

*Date of Meeting:* September 23–25, 1997 from 0800 to 1700.

*Place:* National Highway Institute Conference Room 302, 901 North Stuart Street, Arlington, VA.

*Matters to be Considered:* Research and Development proposals and continuing projects requesting Strategic Environmental Research and Development Program funds in excess of \$1M will be reviewed.

This meeting is open to the public. Any interested person may attend, appear before, or file statements with the Scientific Advisory Board at the time and in the manner permitted by the Board.

*For Further Information Contact:* Ms. Amy Levine, SERDP Program Office, 901 North Stuart Street, Suite 303, Arlington, VA or by telephone at (703) 696–2124.

Dated: August 22, 1997.

**L.M. Bynum,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 97–22862 Filed 8–27–97; 8:45 am]

BILLING CODE 5000–04–M

## DEPARTMENT OF DEFENSE

### Department of the Air Force

#### Record of Decision (ROD) for the Disposal and Reuse Final Environmental Impact Statement for McClellan Air Force Base (AFB), California (CA)

On August 19, 1997, the Air Force issued a ROD for the disposal of McClellan Air Force Base (AFB), CA. The decisions included in this ROD have been made in consideration of the Final Programmatic Environmental Impact Statement for the Disposal and Environmental Impact Report for Reuse (FPEIS/EIR) of McClellan AFB, CA, which was filed with the Environmental Protection Agency on July 3, 1997, and other relevant considerations.

McClellan AFB will officially close on July 13, 2001, pursuant to the Defense Base Closure and Realignment Act of 1990, (Pub. L. 101–510) and the recommendations of the Defense Secretary's Commission on Base Realignment and Closure. This ROD documents the McClellan AFB disposal decisions.

The Air Force has decided to dispose of the approximately 3,452 acres fee and 93 acres of easements of McClellan AFB and associated off base sites in the following manner: Parcel A (approximately 6 acres), Parcel B (approximately 8 acres), Parcel C (approximately 13 acres), Parcel D1 (approximately 1 acre), Parcel E (approximately 14 acres), Parcel F (approximately 3 acres) will be retained by Department of Defense; Parcel G (approximately 5 acres) and Camp

Kohler Annex (approximately 35 acres) will be transferred to the Department of Transportation Federal Aviation Administration for aviation use; Parcel H (approximately 39 acres) will be transferred to the County of Sacramento Board of Supervisors which is the official Local Redevelopment Authority (LRA) for federal leaseback for the Department of Transportation United States Coast Guard for air rescue operations; Parcel I (approximately 1 acre) and McClellan Hospital Complex (approximately 26 acres) will be transferred to the Department of Veterans Affairs for a hospital and dental clinic; Parcel J (approximately 2,415 acres) will be transferred to the LRA for the establishment of an aviation technology center; Parcel K (approximately 1 acre) will be offered as a negotiated sale to Sacramento Area Federal Employees (SAFE) Credit Union; Parcel DC–1 (approximately 115 acres) will be transferred to the Department of Interior United States Fish and Wildlife Service to protect and manage natural habitats and wetlands; and Parcel DC–2 (approximately 5 acres) will be transferred to the Department of Commerce National Oceanic and Atmospheric Administration National Weather Service for weather surveillance. The decision on the remaining land and facilities has been deferred until a later date.

The uses proposed for the property by the prospective recipients of the property under the ROD are included in the proposed action in the FPEIS/EIR and are consistent with the community's revised redevelopment plan for the base. The LRA prepared the plan with the assistance of the broader community.

By this decision, the Air Force adopts certain mitigation measures, as described in this ROD, to protect public health and the environment. In response to the existing or forecasted environmental impacts to or in the area of McClellan AFB, subsequent property owners should consider implementation of the more specific mitigation measures associated with reuses they may undertake, as set forth in Chapter 4 of the PFEIS.

Any questions regarding this matter should be directed to Mr. Charles R. Hatch, Program Manager, Division C. Correspondence should be sent to AFBCA/DC, 1700 North Moore Street, Suite 2300, Arlington, VA 22209–2809.

**Barbara A. Carmichael,**

*Alternate Air Force Federal Register Liaison Officer.*

[FR Doc. 97–22965 Filed 8–27–97; 8:45 am]

BILLING CODE 3910–01–P

## DEPARTMENT OF DEFENSE

### Department of the Army

#### Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning "Bacterial Superantigen Vaccines"

**AGENCY:** U.S. Army Medical Research and Materiel Command, DoD.

**ACTION:** Notice of availability.

**SUMMARY:** In accordance with 38 CFR 404.6, announcement is made of the availability of U.S. Patent Application SN 08/882,431 entitled "Bacterial Superantigen Vaccines." This patent has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, MD 21702–5012.

**FOR FURTHER INFORMATION CONTACT:** Mr. John F. Moran, Patent Attorney, 301–619–7807, Fax 301–619–5034.

#### **SUPPLEMENTARY INFORMATION:**

"Recombinant vaccines for control of bacterial superantigen-associated diseases have been developed. These include vaccines of staphylococcal enterotoxin A, staphylococcal enterotoxin B, staphylococcal enterotoxin C1, toxic-shock syndrome toxin-1, and streptococcal pyrogenic exotoxin-A. Engineered changes in the proteins have attenuated receptor binding and biological activity to an essentially nonspecific level. The vaccines retain a high degree of antigenicity and have been successfully tested in murine and nonhuman primate animal models for protective immunity and safety. These vaccines offer the safety and advantages of defined recombinant proteins and may be useful for controlling toxic-shock syndromes and certain autoimmune diseases associated with these bacterial superantigens."

**Gregory D. Showalter,**

*Army Federal Register Liaison Officer.*

[FR Doc. 97–22872 Filed 8–27–97; 8:45 am]

BILLING CODE 3710–08–M

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Defense Intelligence Agency, Science and Technology Advisory Board Closed Meeting

**AGENCY:** Defense Intelligence Agency, Department of Defense.